Regulation of Deinococcus radiodurans RecA Protein Function via Modulation of Active and Inactive Nucleoprotein Filament States*
- ↵1 To whom correspondence should be addressed: Dept. of Biochemistry, University of Wisconsin-Madison, 433 Babcock Dr., Madison, WI 53706-1544. Tel.: 608-262-1181; Fax: 608-262-2603; E-mail: cox{at}biochem.wisc.edu.
Abstract
The RecA protein of Deinococcus radiodurans (DrRecA) has a central role in genome reconstitution after exposure to extreme levels of ionizing radiation. When bound to DNA, filaments of DrRecA protein exhibit active and inactive states that are readily interconverted in response to several sets of stimuli and conditions. At 30 °C, the optimal growth temperature, and at physiological pH 7.5, DrRecA protein binds to double-stranded DNA (dsDNA) and forms extended helical filaments in the presence of ATP. However, the ATP is not hydrolyzed. ATP hydrolysis of the DrRecA-dsDNA filament is activated by addition of single-stranded DNA, with or without the single-stranded DNA-binding protein. The ATPase function of DrRecA nucleoprotein filaments thus exists in an inactive default state under some conditions. ATPase activity is thus not a reliable indicator of DNA binding for all bacterial RecA proteins. Activation is effected by situations in which the DNA substrates needed to initiate recombinational DNA repair are present. The inactive state can also be activated by decreasing the pH (protonation of multiple ionizable groups is required) or by addition of volume exclusion agents. Single-stranded DNA-binding protein plays a much more central role in DNA pairing and strand exchange catalyzed by DrRecA than is the case for the cognate proteins in Escherichia coli. The data suggest a mechanism to enhance the efficiency of recombinational DNA repair in the context of severe genomic degradation in D. radiodurans.
- ATPases
- DNA
- DNA Enzymes
- DNA Recombination
- DNA Repair
- Electron Microscopy (EM)
- Deinococcus radiodurans
- RecA
- SSB
Footnotes
-
↵* This work was supported, in whole or in part, by National Institutes of Health Grant GM32335 from the NIGMS (to M. M. C.). This work was also supported by an Advanced Opportunity Fellowship from the University of Wisconsin College of Agricultural and Life Sciences and a Genentech predoctoral fellowship (both to K. V. N.). Michael M. Cox is a board member and shareholder of Recombitech, Inc., which is applying recombinational DNA repair to problems in medical diagnostics. His relationship to the company is managed by the University of Wisconsin-Madison in accordance with its conflict of interest policies.
- Received February 4, 2013.
- Revision received May 22, 2013.
- © 2013 by The American Society for Biochemistry and Molecular Biology, Inc.











